{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T09:57:05Z","timestamp":1777111025732,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s13730-019-00404-5","type":"journal-article","created":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T11:17:57Z","timestamp":1559387877000},"page":"256-260","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A case of entecavir-induced Fanconi syndrome"],"prefix":"10.1007","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6498-5668","authenticated-orcid":false,"given":"Teruhiro","family":"Fujii","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Kawasoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihito","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosaku","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,1]]},"reference":[{"key":"404_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1\u201398. \n                    https:\/\/doi.org\/10.1007\/s12072-015-9675-4\n                    \n                  .","journal-title":"Hepatol Int"},{"key":"404_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH, American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261\u201383. \n                    https:\/\/doi.org\/10.1002\/hep.28156\n                    \n                  .","journal-title":"Hepatology"},{"key":"404_CR3","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1002\/hep.22885","volume":"49","author":"RJ Fontana","year":"2009","unstructured":"Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 2009;49:S185\u201395. \n                    https:\/\/doi.org\/10.1002\/hep.22885\n                    \n                  .","journal-title":"Hepatology"},{"key":"404_CR4","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1111\/j.1365-2036.2012.05093.x","volume":"35","author":"N Gara","year":"2012","unstructured":"Gara N, Zhao X, Collins MT, Chong WH, Kleiner DE, Jake Liang T, Ghany MG, Hoofnagle JH. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther. 2012;35:1317\u201325. \n                    https:\/\/doi.org\/10.1111\/j.1365-2036.2012.05093.x\n                    \n                  .","journal-title":"Aliment Pharmacol Ther"},{"key":"404_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/qjmed\/hct258","volume":"107","author":"AM Hall","year":"2014","unstructured":"Hall AM, Bass P, Unwin RJ. Drug-induced renal Fanconi syndrome. QJM. 2014;107:261\u20139. \n                    https:\/\/doi.org\/10.1093\/qjmed\/hct258\n                    \n                  .","journal-title":"QJM"},{"key":"404_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/s2468-1253(16)30024-3","volume":"1","author":"HL Chan","year":"2016","unstructured":"Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, Hui AJ, Janssen HL, Chowdhury A, Tsang TY, Mehta R, Gane E, Flaherty JF, Massetto B, Gaggar A, Kitrinos KM, Lin L, Subramanian GM, McHutchison JG, Lim YS, Acharya SK, Agarwal K, GS-US-320-0110 Investigators. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1:185\u201395. \n                    https:\/\/doi.org\/10.1016\/s2468-1253(16)30024-3\n                    \n                  .","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"404_CR7","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1081\/NCN-100002341","volume":"20","author":"T Cihlar","year":"2001","unstructured":"Cihlar T, Ho ES, Lin DC, Mulato AS. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides, Nucleotides Nucleic Acids. 2001;20:641\u20138.","journal-title":"Nucleosides, Nucleotides Nucleic Acids"},{"key":"404_CR8","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1124\/mol.106.028233","volume":"71","author":"T Imaoka","year":"2007","unstructured":"Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Functional involvement of multidrug resistance-associated protein 4 (MRP4\/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol. 2007;71:619\u201327.","journal-title":"Mol Pharmacol"},{"key":"404_CR9","doi-asserted-by":"publisher","first-page":"6260","DOI":"10.1128\/AAC.00986-16","volume":"60","author":"X Yang","year":"2016","unstructured":"Yang X, Ma Z, Zhou S, Weng Y, Lei H, Zeng S, Li L, Jiang H. Multiple drug transporters are involved in renal secretion of entecavir. Antimicrob Agents Chemother. 2016;60:6260\u201370. \n                    https:\/\/doi.org\/10.1128\/AAC.00986-16\n                    \n                  .","journal-title":"Antimicrob Agents Chemother"},{"key":"404_CR10","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3389\/fphar.2015.00304","volume":"6","author":"J Mand\u00edkov\u00e1","year":"2016","unstructured":"Mand\u00edkov\u00e1 J, Volkov\u00e1 M, P\u00e1vek P, Navr\u00e1tilov\u00e1 L, Hyr\u0161ov\u00e1 L, Janeba Z, Pavl\u00edk J, B\u00e1rta P, Trejtnar F. Entecavir Interacts with influx transporters hOAT1, hCNT2, hCNT3, but not with hOCT2: the potential for renal transporter-mediated cytotoxicity and drug-drug interactions. Front Pharmacol. 2016;6:304. \n                    https:\/\/doi.org\/10.3389\/fphar.2015.00304\n                    \n                  .","journal-title":"Front Pharmacol"},{"key":"404_CR11","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/hep.23044","volume":"50","author":"NB Ha","year":"2009","unstructured":"Ha NB, Ha NB, Garcia RT, Trinh HN, Vu AA, Nguyen HA, Nguyen KK, Levitt BS, Nguyen MH. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology. 2009;50:727\u201334. \n                    https:\/\/doi.org\/10.1002\/hep.23044\n                    \n                  .","journal-title":"Hepatology"},{"key":"404_CR12","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00228-014-1712-z","volume":"70","author":"A Jafari","year":"2014","unstructured":"Jafari A, Khalili H, Dashti-Khavidaki S. Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention. Eur J Clin Pharmacol. 2014;70:1029\u201340. \n                    https:\/\/doi.org\/10.1007\/s00228-014-1712-z\n                    \n                  .","journal-title":"Eur J Clin Pharmacol"},{"key":"404_CR13","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2169\/internalmedicine.53.1213","volume":"53","author":"H Eguchi","year":"2014","unstructured":"Eguchi H, Tsuruta M, Tani J, Kuwahara R, Hiromatsu Y. Hypophosphatemic osteomalacia due to drug-induced Fanconi\u2019s syndrome associated with adefovir dipivoxil treatment for hepatitis B. Intern Med. 2014;53:233\u20137.","journal-title":"Intern Med"},{"key":"404_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/apt.13659","volume":"44","author":"P Lampertico","year":"2016","unstructured":"Lampertico P, Chan HL, Janssen HL, Strasser SI, Schindler R, Berg T. Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfectedpatients. Aliment Pharmacol Ther. 2016;44:16\u201334. \n                    https:\/\/doi.org\/10.1111\/apt.13659\n                    \n                  .","journal-title":"Aliment Pharmacol Ther"},{"key":"404_CR15","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/apt.14497","volume":"47","author":"GL Wong","year":"2018","unstructured":"Wong GL, Seto WK, Wong VW, Yuen MF, Chan HL. Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. Aliment Pharmacol Ther. 2018;47:730\u20137. \n                    https:\/\/doi.org\/10.1111\/apt.14497\n                    \n                  .","journal-title":"Aliment Pharmacol Ther"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-019-00404-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13730-019-00404-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-019-00404-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T23:28:14Z","timestamp":1590881294000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13730-019-00404-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,1]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["404"],"URL":"https:\/\/doi.org\/10.1007\/s13730-019-00404-5","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,1]]},"assertion":[{"value":"7 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have declared that no Conflict of interest exist.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving Human Participants"}},{"value":"Informed consent was obtained from the participant included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}